Patents Assigned to Chembridge Corporation
  • Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Patent number: 9290503
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 22, 2016
    Assignee: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward Gregor
  • Tyrosine kinase inhibitors
    Patent number: 9273055
    Abstract: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: March 1, 2016
    Assignee: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward Gregor
  • Tyrosine kinase inhibitors
    Patent number: 9249147
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 2, 2016
    Assignee: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward Gregor
  • Tyrosine kinase inhibitors
    Patent number: 8822500
    Abstract: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: September 2, 2014
    Assignee: Chembridge Corporation
    Inventor: Nelson Levy
  • Tyrosine kinase inhibitors
    Patent number: 8815906
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 26, 2014
    Assignee: Chembridge Corporation
    Inventors: Yahua Liu, Alexey Vyacheslavovich Anikin, Charles Chamchoumis Mikel, Douglas Eric McGrath, Goverdhan Reddy Vavilala, Jason Conrad Pickens, Aleksander Kadushkin, Luyong Jiang, Mohan Santhanam Thiruvazhi, Sergey Zozulya, Rajendran Vairagoundar, Tong Zhu, Alexander Chucholowski, Zheng Yan, Alisher Khasanov, Christina Gregor
  • TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS
    Publication number: 20140228350
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 14, 2014
    Applicant: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward GREGOR
  • Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Patent number: 8686005
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: April 1, 2014
    Assignee: Chembridge Corporation
    Inventor: Nelson Levy
  • Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Patent number: 8629147
    Abstract: The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: January 14, 2014
    Assignee: ChemBridge Corporation
    Inventors: Alexey Vyacheslavovich Anikin, Vidyasagar Reddy Gantla, Vlad Edward Gregor, Luyong Jiang, Yahua Liu, Danny Peter Claude McGee, Charles Chamchoumis Mikel, Jason Conrad Pickens, Thomas Roy Webb, Zheng Yan, Tong Zhu, Aleksander Kadushkin, Sergey Sviridov, Sergey Zozulya, Alexander Chucholowski, Douglas Eric McGrath
  • Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Patent number: 8063225
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: November 22, 2011
    Assignee: Chembridge Corporation
    Inventors: Vlad E. Gregor, Yahua Liu, Alexey Anikin, Danny Peter Claude McGee, Charles Mikel, Douglas Eric McGrath, Goverdhan Reddy Vavilala, Jason C. Pickens, Alexander Kadushkin, Luyong Jiang, Mohan Santhanam Thiruvazhi, Sergey Zozulya, Rajendran Vairagoundar, Tong Zhu, Alexander Chucholowski, Thomas Webb, Vidyasagar Reddy Gantla, Zheng Yan